Triglycerides and HDL Cholesterol
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 56 of the 59 references it cites were found in a registry or an index.
Abstract
Diabetes carries a high risk of atherosclerosis, and cardiovascular disease, especially coronary heart disease (CHD) and stroke, is by far the leading cause of death among patients with type 2 diabetes. Although statins reduce the risk of major vascular events by about one-fifth per millimole per liter reduction in LDL cholesterol, with similar proportional reductions in major coronary events, stroke, and the need for coronary revascularization, the residual risk remains high. In the Scandinavian Simvastatin Survival Study (4S) (1), although the relative risk reduction in diabetic patients was larger than in nondiabetic patients, simvastatin-treated diabetic patients were still at higher risk of death than the placebo-treated nondiabetic patients. Multifactorial intervention reduces the risk even further, but significant danger remains. Current guidelines call for an aggressive treatment strategy to reduce LDL cholesterol, blood pressure, and glucose levels in diabetic patients, but data concerning the management of high triglyceride (TG) levels and low HDL cholesterol levels remains inconclusive. This article reviews the data concerning diabetic dyslipidemia and its management. DIABETIC DYSLIPIDEMIA — The cluster of lipid abnormalities associated with type 2 diabetes is defined by a high concentration of TG and small dense LDL and a low concentration of HDL cholesterol. Plasma LDL cholesterol levels are generally normal. Insulin resistance is believed to contribute to this atherogenic dyslipidemia by increasing the hepatic secretion of VLDL and other apolipoprotein (apo)B-containing lipoprotein particles,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Obesity has a clear correlation with the incidence of cardiovascular disorders including hypertension, coronary artery disease, heart failure and sudden death”
In the citing paper
“many patients with insulin resistance, the main etiology of T2DM, tend to have high triglyceride and low HDL levels [53,54,55]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“FUTURE PROSPECTS — The concept of cholesterol ester transfer protein (CETP) inhibition suffered a serious blow when the results of the ILLUMINATE trial demonstrated an increase in adverse events in patients treated with torcetrapib (42).”
BackgroundYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979 · cited 2×
“The simvastatin-niacin combination was also associated with a 90% reduction in the composite end point of major cardiovascular events (32).”
BackgroundFifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824 · cited 1×
“In the Coronary Drug Project, niacin reduced mortality among myocardial infarction survivors, although, contrary to the relatively rapid effect of statins, mortality rates were almost identical throughout the first 68 months of follow-up and did not begin to diverge until month 72 (31).”
ResultNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707 · cited 1×
“In one small study, intravenous recombinant apoA-I Milano/phospholipid complexes produced regression of coronary atherosclerosis as measured by intravascular ultrasound (44).”
BackgroundHokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706 · cited 1×
“In a meta-analysis of 17 population-based prospective studies, increased plasma TG levels were associated with increased coronary disease risk in both men and women, after adjustment for HDL cholesterol and other risk factors (7).”
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
Cited by
Items 101–138 of 138
Ejercicio físico, calidad de vida y salud de diabéticos tipo 2
da Silva, F. C., Iop, R. D. R., Arancibia, B. A. V., Filho, P. J. B. G., da Silva, R., Machado, M. D. O., & Moro, A. R. P. (2017) · Revista de psicología del deporte · Cited by 36
Ikewuchi, J. C., Ikewuchi, C. C., Ifeanacho, M. O., Igboh, N. M., Ijeh, I. I., & Ihunwo, S. A. (2013) · Journal of Experimental and Applied Animal Sciences · doi:10.20454/jeaas.2013.708 · Cited by 3
Lehmann, D. F., & SITAR, D. S. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011420253 · Cited by 3
“Second, aggravating this phenomenon is that they are also frequently associated with, but not necessarily causal of, endocrinopathies with complex pathophysiology, most notably type 2 diabetes.(6) Third, although improvement in the serum levels of both lipid abnormalities is correlated with improved cardiovascular out…”
BackgroundMa, Y., Zhou, Z., Li, X., Ding, K., Xiao, H., Wu, Y., Wu, T., & Chen, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1009095 · Cited by 4
Lipid peroxidation, antioxidants, lipid profile, and HbA1c in diabetic patients
Thanpari, C., Takhelmayum, R., Yadav, N. K., Shrewastwa, M. K., Manger, P. T., & Mittal, R. K. (2015) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-015-0356-6 · Cited by 3
Mokale, S. N., Dube, P. N., Nevase, M. C., Sakle, N. S., Shelke, V. R., Bhavale, S. A., & Begum, A. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1498-2 · Cited by 2
“Fibrates affect lipid metabolism as agonists of enzyme peroxisome proliferatoractivated receptor alpha (PPAR-a) by lowering TG, LDL and by increasing HDL cholesterol level (Bitzur et al., 2009; Mokale et al., 2012b).”
BackgroundBai, H., Xia, L., Song, L., Long, Z., Wu, Y., Ru, J., Li, Y., Ni, X., Wang, Z., & Liao, L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1829984 · Cited by 2
Cardio-Metabolic Benefits of Walnuts in Type 2 Diabetes Mellitus: A Literature Review
Njike, V. Y., Kela, G., Khan, N., Ayettey, R. G., Tindong, M., Treu, J. A., & Costales, V. C. (2021) · European Medical Journal · doi:10.33590/emj/21-00070 · Cited by 2
Ogawa, K., Tsoi, L. C., Tanaka, H., Kanai, M., Stuart, P. E., Nair, R. P., Tanaka, Y., Mochizuki, H., Elder, J. T., & Okada, Y. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.01.037 · Cited by 2
Bioassay-guided Isolation and Identification of Antidiabetic Compounds from Naregamia alata
Rodrigues, W. J., Nekrakaleya, B., Ramaiah, C. K., & Boja Poojary, B. (2023) · Current Bioactive Compounds · doi:10.2174/1573407219666230413081819 · Cited by 2
Lipid management in Type 2 diabetes: the case for combination therapy?
Saely, C. H., Drexel, V., Vonbank, A., & Drexel, H. (2011) · Therapy · doi:10.2217/thy.11.5 · Cited by 2
Repetition of Prediabetes Enhances the Risk of Developing Diabetes
Numata, Y., Ohya, T., Nitta, Y., Yoshinaka, Y., Shogakiuchi, A., & Toyota, A. (2019) · Journal of Diabetes Research · doi:10.1155/2019/4916546 · Cited by 3
Annapurna, V., Rajkumar, H., Raviteja, A., Avs., R., Babu, K. N., Thirupathaiah, Y., Shujauddin, M., Nemani, H., & Balakrishna, N. (2015) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 1
Pegolo, G. E. (2015) · Segurança Alimentar e Nutricional · doi:10.20396/san.v19i2.8634611 · Cited by 1
Study of Serum Betatrophin Level in The Patients of Type 2 Diabetes Mellitus
El-Ghandour, A. H., El-Bendary, A. S., Shahba, A., & Soliman, G. A. (2019) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2019.28682 · Cited by 1
Teixeira, L. F., Bidu, N. S., da Silva, A. L. M., da Conceição, G. C., Brustolim, D., Aras, R., & Couto, R. D. (2024) · The Open Biomarkers Journal · doi:10.2174/0118753183290270240319075030 · Cited by 1
Fedko, I. O., Nivard, M. G., Hottenga, J., Zudina, L., CHARGE Inflammation working group Cross Consortia Pleiotropy (XC-Pleiotropy) Group, Balkhiyarova, Z., Chasman, D. I., Ganesh, S. K., Huang, J., Nalls, M. A., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/496802 · Cited by 1
Diabetes management by primary health care nurses in Auckland: A cross-sectional study
Daly, B. M. (2012) · ResearchSpace (University of Auckland) · Cited by 2
Sau, T. J., Dey, S. K., Kumar, A., & Biswas, U. K. (2013) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v5i1.8450
Saadallah, N. M., & Yassin, M. M. (2013) · Cited by 2
Regional heterogeneity of the vascular dysfunction in db/db mice : role of reactive oxygen species
Sallam, N. A. (2012) · cIRcle (University of British Columbia) · doi:10.14288/1.0103453
“In addition to the role of HDL particles in the uptake of peripheral cholesterol to the liver, they exhibit anti-inflammatory, antithrombotic and antioxidant properties (Bitzur et al., 2009).”
BackgroundOptimal Carbohydrate and Nutrient Intake for Japanese Elderly Patients with Type 2 Diabetes
Kamada, C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800093-9.00025-9
Guivarc’H, E. (2017) · theses.fr (ABES) · doi:10.70675/7464f3a5z1ed8z4814za161z5174483ba24c
Soh, R. M., Oumbe, V. A. S., Ngondi, J. L., & Oben, J. E. (2020) · Clinical Phytoscience · doi:10.1186/s40816-020-00218-4
Chandra, S., & Sorrentino, M. J. (2011) · Humana Press eBooks · doi:10.1007/978-1-60327-502-6_8
Brinton, E. A., & Pulipati, V. P. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_24
Stars and Rising Stars in Pediatric Endocrinology: 2022
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4686-4
Harrison, L., Schriever, S. C., Bernecker, M., Mallet, N., Castillejo, C. M., Ameli, H., Baumann, P., Contreras, R. E., Stolz, J., Lindner, R., et al. (2025) · Diabetes · doi:10.2337/db24-0502
Abou‐El‐Naga, A. M., Ghaweet, H. M. E., Abdeen, S. H., El-Sheikhe, Z. S., & Mansour, H. A. E. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-025-10658-2
“These find - ings may be explained by the connection between insulin resistance, a risk factor for diabetes, and diabetic dyslipi-daemia, which increases the risk of heart attack and stroke (Bitzur et al. 2009; Han and Choi 2023).”
Stroster, J. A. (2013) · UA Campus Repository (The University of Arizona)
Li, M., Zhang, W., Zhang, M., Li, L., Wang, D., Yan, G., Qiao, Y., & Tang, C. (2024) · Figshare · doi:10.6084/m9.figshare.26664112
盛国太, Kuang, M., Yang, R., Zhong, Y., Zhang, S., & Zou, Y. (2022) · Figshare · doi:10.6084/m9.figshare.20056748
盛国太, Kuang, M., Yang, R., Zhong, Y., Zhang, S., & Zou, Y. (2022) · Figshare · doi:10.6084/m9.figshare.20056751
Li, M., Zhang, W., Zhang, M., Li, L., Wang, D., Yan, G., Qiao, Y., & Tang, C. (2024) · Figshare · doi:10.6084/m9.figshare.26664118
盛国太, Kuang, M., Yang, R., Zhong, Y., Zhang, S., & Zou, Y. (2022) · Figshare · doi:10.6084/m9.figshare.20056754
Li, M., Zhang, W., Zhang, M., Li, L., Wang, D., Yan, G., Qiao, Y., & Tang, C. (2024) · Figshare · doi:10.6084/m9.figshare.26664124
(2014) · Arizona State University Library Digital Repository (Arizona State University)
Łozicki, A., & Dymnicka, M. (2014) · Journal of Animal and Feed Sciences · doi:10.22358/jafs/65715/2014
Metadata
- Authors
- Bitzur, R., Cohen, H., Kamari, Y., Shaish, A., & Harats, D.
- Affiliations
- Sheba Medical Center (IL)
- Corresponding author
- Bitzur, Rafael
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-11-01
- Volume
- 32
- Issue
- suppl_2
- Pages
- S373-S377
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2811435
- OpenAlex
- W2170606689
- Cited by
- 132
- References
- 59
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 9 · 2023: 5 · 2022: 10 · 2021: 16 · 2020: 14 · 2019: 6 · 2018: 10 · 2017: 9 · 2016: 10 · 2015: 9 · 2014: 9 · 2013: 8 · 2012: 5
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- triglycerides, HDL cholesterol, type 2 diabetes, diabetic dyslipidemia, residual cardiovascular risk, statins, small dense LDL, insulin resistance, atherogenic dyslipidemia, cardiovascular disease, lipid control
- MeSH terms
- Cardiovascular Diseases, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Cholesterol, HDL, Niacin, Triglycerides, Fatty Acids, Omega-3, Stroke, PPAR alpha, Diabetes Complications, Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.